Abstract
"CLO23-051: Real-World Use of Neratinib in Patients With HER2-Positive Early-Stage Breast Cancer Following Prior Ado-Trastuzumab Emtansine (T-DM1) or Dual HER2 Blockade With Pertuzumab Plus Trastuzumab" published on 31 Mar 2023 by National Comprehensive Cancer Network.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the National Comprehensive Cancer Network
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
